Business · 09/10/2009Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for ENTEREG Patent Extension
Summary
The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for ENTEREG, a human drug product, in accordance with federal regulations, following a formal submission to the Director of Patents and Trademarks at the Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →